| We critically reviewed (second-generation) multiple sclerosis therapeutics licensed since 2018 until 2022 and the outlook regarding new substance classes. |
| Differing modes of action, routes of application, and side-effect profiles allow a personalized treatment approach. |
| Substances to come include a new anti-CD20 therapeutic, ublituximab, and inhibitors of Bruton’s tyrosine kinase as a new class of medications acting both on B cells and myeloid cells. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.